Preschol

Quick links to important sections

Preschol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Preschol

Quick Facts: Preschol

Property Description
Active ingredient Simvastatin
Form Tablet (Oral route)
Pharmacological class HMG-CoA reductase inhibitor (Statin)
General purpose Lipid-lowering agent
Origin Semi-synthetic derivative

Preschol is a prescription-only medication primarily identified by its active component, Simvastatin, and belongs to the general statin family of drugs, which are widely recognized for managing blood lipid levels.


What Type of Medicine is Preschol? (Classification and Identity)

Preschol is scientifically classified as an HMG-CoA reductase inhibitor, a categorization that places it within the general statin pharmacological class. As a statin, it serves as a standard agent in managing high cholesterol. Preschol is a therapeutic tool for systemic lipid control, clinically recognized for its established role in primary dyslipidemia management. Its typical administration is via an oral route tablet, containing Simvastatin as the sole active pharmaceutical ingredient, positioning it as a foundational, single-entity agent.


What is Simvastatin Made Of and How Does It Act? (Composition and Origin)

The core component is Simvastatin, a semi-synthetic derivative that functions as a prodrug. This structure means the body must metabolically convert it into the fully active compound, simvastatin hydroxy acid, to exert its primary effects. Simvastatin acts by engaging in competitive inhibition, directly targeting the enzyme HMG-CoA reductase in the liver. This mechanism works by inhibiting the rate-limiting step of cholesterol synthesis.


What is the General Purpose of Preschol? (Core Therapeutic Goal)

The general purpose of Preschol is to act as a potent lipid-lowering drug to correct imbalances in blood fat levels, professionally referred to as dyslipidemia. A typical neutral use scenario for Preschol is its application in managing elevated levels of low-density lipoprotein cholesterol (LDL-C), often known as "bad" cholesterol. By intervening in cholesterol production, the medicine aids in lowering LDL-C and supports the body in clearing excess cholesterol from the bloodstream, a therapeutic objective that helps manage hypercholesterolemia.

Regulatory References

  1. MedlinePlus: Simvastatin
  2. FDA Drug Label: Simvastatin

What side effects are possible with Preschol?

Preschol: Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety characteristics of Preschol (Simvastatin), based on regulatory documents from government health authorities. Adverse reactions are classified by frequency and the body system affected, consistent with the framework used in official prescribing information.


Adverse Reaction Scope and Classification

The regulatory profile identifies several System Organ Classes involved, including Musculoskeletal and Connective Tissue Disorders, Gastrointestinal Disorders, and Hepatobiliary Disorders. These systems host events ranging from common to rare, as defined in official labeling.

Classification Example Adverse Reaction (Regulatory Documentation)
Common (ge 1/100 to < 1/10) Myalgia (Muscle Pain), Constipation, Asthenia (Weakness)
Rare (ge 1/10,000 to < 1/1,000) Myopathy, Elevated Liver Transaminases, Hypersensitivity reactions

Serious Adverse Reactions and Safety Constraints

Official documents highlight the risk of serious adverse reactions, most notably Rhabdomyolysis (severe muscle breakdown), Hepatic Failure, and severe Hypersensitivity Reactions such as Angioedema. These events are rare but considered clinically significant.

Safety constraints are specified for certain populations. The medicine is generally contraindicated in individuals with Active Liver Disease and unexplained persistent elevations of serum transaminases. Official labeling also notes that the risk of myopathy is dose-dependent and increases when Preschol is co-administered with potent inhibitors of Cytochrome P450 3A4 (CYP3A4), which is a high-level safety limitation. Patients with severe renal impairment require specific safety considerations.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents characterize the overdose profile of Preschol (Simvastatin) based primarily on documented human case reports. In these reports, including those involving doses as high as 3.6 g, patients who took an overdose recovered without sequelae.

Documented Manifestations and Management

Domain Regulatory Statement Summary
Symptom Profile No specific, consistent symptom profile is officially documented in human overdose cases.
Antidote Availability No specific antidotes for Simvastatin tablets are known.
Supportive Care Management should consist of supportive measures that are symptomatic in nature.
Procedural Note The dialyzability of Simvastatin and its metabolites is not known.

Required Emergency Action

Immediate professional guidance is required in the event of an overdose. Official prescribing information mandates the action to Contact Poison Control (1-800-222-1222) for the latest recommendations. The requirement to seek immediate medical help is established to ensure the prompt initiation of supportive measures and professional assessment, even though documented cases have reported favorable outcomes.

Therapeutic Uses of Preschol

Main Uses and Benefits of Preschol

Preschol is a pharmacological intervention primarily used in the management of lipid profiles. Its application is centered on the regulation of cholesterol levels within the bloodstream, specifically targeting individuals who require assistance in reaching lipid targets that cannot be achieved through lifestyle modifications alone.

Primary Indications

The medication is indicated for the treatment of various forms of hyperlipidemia. This includes conditions characterized by elevated levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C). By addressing these elevations, the medication supports the maintenance of vascular health.

  • Primary Hypercholesterolemia: Used in patients with high levels of LDL-C to assist in lowering these concentrations to a more manageable range.
  • Mixed Dyslipidemia: Employed when a patient exhibits a complex profile of lipid imbalances, involving multiple types of cholesterol or fats in the blood.
  • Homozygous Familial Hypercholesterolemia: Utilized as an adjunctive therapy in genetic conditions where cholesterol levels are inherently and severely elevated.

Therapeutic Benefits

The primary benefit of Preschol is its ability to modify the lipid environment, which is a key factor in long-term cardiovascular health. By effectively lowering LDL-C, the medication helps to reduce the accumulation of fatty deposits in the arterial walls.

Impact on Lipid Profiles

Preschol works by inhibiting specific pathways involved in cholesterol production and absorption. The physiological benefits observed during treatment typically include:

  • Reduction of LDL-C: Often referred to as "bad" cholesterol, reducing this component is the primary goal of therapy to prevent arterial plaque formation.
  • Reduction of Apolipoprotein B: Lowering this protein component helps in managing the total number of atherogenic particles in circulation.
  • Modest Increase in HDL-C: While not the primary focus, the medication can contribute to a slight rise in high-density lipoprotein cholesterol, which assists in transporting cholesterol away from the arteries.

Role in Long-Term Management

Preschol serves as a stabilizing component in a broader health strategy. Its benefits are most pronounced when integrated into a comprehensive approach to metabolic health. While it focuses on biochemical markers, the objective is to improve the overall vascular environment and support the functional integrity of the circulatory system over time.

Regulatory References

  1. NIH DailyMed website

Eligibility and Restrictions for Use

Who Can and Cannot Use Preschol?

This section details population eligibility for Preschol (Simvastatin), based strictly on official regulatory documents. Eligibility is defined by absolute contraindications, restrictions, and age requirements.


Populations Contraindicated (Must Not Use)

Preschol is contraindicated in several specific populations, meaning use is formally prohibited:

  • Women who are pregnant or may become pregnant, and nursing mothers (breastfeeding).
  • Patients with active liver disease, including unexplained persistent elevations of hepatic transaminases.
  • Patients taking specific strong CYP3A4 inhibitors (e.g., certain macrolide antibiotics or HIV protease inhibitors).

Age and Condition Restrictions

Use is approved for Adults for all labeled indications. Pediatric use is restricted:

  • Age-Based Eligibility: Only approved for pediatric patients aged 10 years and older (post-menarcheal girls) specifically for Heterozygous Familial Hypercholesterolemia (HeFH). Safety and efficacy are not established for children under 10.
  • Conditional Use: Patients with severe renal impairment or certain predisposing factors for muscle disorders—such as uncontrolled hypothyroidism or a history of hereditary muscular disorders—fall into a restricted-use category that requires caution.

What should I know about interactions with other medicines?

Preschol (Simvastatin) has officially documented interaction patterns that are classified based on the resulting risk to the patient. Interactions primarily involve the drug's metabolism by the CYP3A4 enzyme and transport via the OATP1B1 protein. Certain medicinal products are considered contraindicated for co-administration due to the significant elevation of simvastatin plasma concentrations, which increases the risk of severe muscle effects. These prohibited combinations include strong CYP3A4 inhibitors (e.g., specific azole antifungals, macrolide antibiotics, HIV protease inhibitors, and Nefazodone), Gemfibrozil, Cyclosporine, and Danazol.

For other interacting agents, regulatory documents mandate maximum dose restrictions to manage exposure risk. For instance, the maximum daily dose of Preschol is restricted to 20 mg when taken with Amiodarone, Amlodipine, or Ranolazine. The maximum dose is further restricted to 10 mg with Verapamil, Diltiazem, or Dronedarone.

The drug's profile also details pharmacodynamic interactions, where co-administration with products like Colchicine or lipid-modifying doses of Niacin (1 g/ day) carries an additive risk of myopathy. Furthermore, the regulatory label notes that consumption of Grapefruit Juice can significantly increase simvastatin plasma levels, and a required timing rule specifies that Preschol must be taken separated from bile acid sequestrants by at least two to four hours. The label also notes an increased myopathy risk for Chinese patients taking high-dose Niacin.

Mechanism of Action

How Preschol Works

Preschol influences signal transduction by engaging multiple distinct molecular and cellular processes. Its activity is directed toward pathways characterized by heightened or dysregulated signal flux.


Receptor-Mediated Signal Dampening

This domain covers the drug's primary action on specific cell-surface receptors. Preschol initiates or suppresses signaling sequences at these receptor sites, leading to an overall reduction in the magnitude of signal transmission within the targeted pathways.


Enzyme Pathway Modulation

The second key domain involves the regulation of pivotal enzymatic cascades. Preschol modifies the early molecular steps within a distinct metabolic or signaling pathway by altering the activity of a rate-limiting enzyme. This action results in a diminished concentration of specific downstream mediators.


Feedback Loop Regulation

Preschol engages mechanisms that influence the dynamic, internal feedback regulation within targeted pathways. It modifies the ratio of activating and inhibitory signal components, altering pathway kinetics.

Dosage and Administration Information

How Preschol Is Used: Official Administration Guidelines

Preschol (Simvastatin) is an oral medication with administration instructions established to ensure standardized usage. The medicine is prescribed for chronic, long-term management and is designed to be taken once daily in the evening, an established scheduling pattern across its approved uses.

Dosing and Frequency

The standard adult dosing range typically begins at 10 mg to 20 mg once daily, with a usual maintenance range extending up to 40 mg once daily. The 40 mg dose represents the generally recommended maximum daily dose. Adjustments to the dose, when deemed necessary by the prescribing clinician, are required to be implemented at intervals of four weeks or more to allow for proper assessment of the response.

Administration Conditions

Preschol tablets can be taken with or without food. If a dose is missed, instructions are to take it as soon as possible, but to not double the dose to compensate for the skipped one. Special use constraints govern co-administration with other treatments: for instance, Simvastatin must be taken at least 2 hours before or 4 hours after a bile acid sequestrant.

Population-Specific Use

Specific dosage guidance is outlined for certain populations. For adult patients with severe renal impairment (creatinine clearance < 30 mL/min), the recommended starting dose is 5 mg once daily. In pediatric patients (10–17 years) being treated for Heterozygous Familial Hypercholesterolemia (HeFH), the maximum recommended dose remains 40 mg daily, mirroring the general adult maximum.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research has explored the compound's activity in laboratory models. A major randomized, placebo-controlled study, known as the Preschool ADHD Treatment Study (PATS), examined the compound's use in children aged 3 to 5 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

Studies evaluated whether the compound might be associated with changes in core ADHD symptoms compared to a placebo. The trials followed an initial period of behavioral therapy and only included children with severe, persistent symptoms.

Investigators assessed the compound's potential impact on behavior. Studies used specific administration protocols in the context of the trial design.


Long-Term Data and Outcomes

The PATS study included a comparison of the compound against placebo. Researchers evaluated whether there was an association between the compound and a reduction in ADHD symptoms. The study found that different children responded best to different doses, suggesting the need for careful individual adjustment. An average daily dose for the study group was identified.

Regarding physical health, the study noted a difference in average growth rates (height and weight) between the medicated group and the expected growth rates for the general population over the study's duration.

Studies have focused on the pediatric patient population. The research population for the medication phase of the trial did not include participants who had active infections at the time of study initiation.


Safety Profile Findings

The trial tracked various potential adverse effects. While a large percentage of participants were observed to tolerate the compound, approximately 1 in 10 children had to withdraw from the study due to intolerable side effects. Reported side effects included loss of appetite, insomnia, and mood disturbances like irritability or withdrawal. These findings suggest that preschoolers may be more sensitive to the compound's adverse effects than older children, emphasizing the importance of close monitoring.

Frequently Asked Questions (FAQ)

Common questions about Preschol (FAQ)

Q: How does Preschol's effect compare to other similar treatments, generally speaking?

Preschol belongs to the statin family of medicines, which are scientifically classified as HMG-CoA reductase inhibitors. Official information states these agents are clinically recognized for their established role in managing high blood lipid (fat) levels. This classification places it in the same general therapeutic category as other lipid-lowering drugs.


Q: Are the side effects of Preschol generally considered mild or severe?

Official prescribing information classifies adverse events by how often they occur. Reactions range from common effects, such as muscle pain or weakness, to rare but serious risks, which include severe muscle breakdown (rhabdomyolysis) or liver problems. The complete safety profile is detailed in the official regulatory documents.


Q: Is the fatigue some people report a normal initial side effect of Preschol?

The official product profile lists Asthenia, which refers to weakness or lack of energy, as a common adverse reaction. This means the side effect was reported in 1% to 10% of participants in clinical trials. Information regarding the exact timeline for when this effect may start or stop is generally not detailed in regulatory documents.


Q: Can Preschol cause dizziness or lightheadedness?

Regulatory documents mention Dizziness as an adverse reaction that has been observed. This symptom is typically classified as a less common or rare event within the drug's full safety profile.


Q: Is it safe to drive or operate machinery while taking Preschol?

Official guidance indicates that Preschol is not generally expected to impair the ability to drive or operate machinery. However, regulatory warnings indicate that rare adverse reactions, such as dizziness, could potentially affect a person's coordination or alertness.


Q: Does Preschol affect birth control pills?

The drug interaction section of official prescribing information details all known clinically significant interactions. This section does not list hormonal birth control pills as a medicine that interacts with Preschol.


Q: How does Preschol affect the kidneys?

Preschol's primary effect is on lipid levels, but regulatory documents address kidney function in the context of dosing. For adult patients with severe renal insufficiency, official dosage guidance recommends careful consideration when prescribing doses above 10, mg/day. Specific official guidance regarding moderate impairment is not generally provided in the same manner as for severe impairment.


Q: Does Preschol have any black box warnings from the FDA?

The highest approved dose of 80, mg of Preschol is subject to a restricted use statement in the official FDA labeling. The restriction reflects regulatory concern over an increased risk of severe muscle injury (myopathy), particularly during the first year of therapy.


Q: Does Preschol cause weight gain or weight loss?

Official prescribing information may list weight gain as a reported adverse reaction within the drug's safety profile. In regulatory documents, this type of event is often classified as a less common or rare finding based on clinical trial data.


Q: How long does it typically take for Preschol to start working?

According to official clinical pharmacology information, the beneficial lipid-lowering effects of Preschol generally begin to be observed within the first two weeks after starting therapy.


Q: What is the timeframe for feeling the full effects of Preschol?

The official guidance for dosage adjustment suggests that a proper assessment of the full therapeutic response requires time. Typically, a patient must wait at least four weeks or more after a dose change before their healthcare professional can accurately evaluate the medicine's effectiveness.


Q: If I miss a day of Preschol, what should I generally expect?

Regulatory guidance related to a missed dose indicates that users should not double the dose to compensate for the skipped one. Although missing a single dose is not expected to pose immediate harm, the medicine's benefits rely on continuous, daily use. Temporarily stopping treatment may lead to a brief rise in cholesterol levels.


Q: Does Preschol affect sleep or cause insomnia?

Official documents list Insomnia (difficulty sleeping) as a reported adverse reaction. This is one of several nervous system events observed in clinical studies and post-marketing surveillance.


Q: Does Preschol interact with caffeine?

The comprehensive drug interaction section found in the official prescribing information does not list caffeine as a substance that interacts with Preschol.


Q: Are there any vitamins or supplements that interact with Preschol?

The official label specifies an interaction with lipid-modifying doses of Niacin, when taken at 1, gram per day or higher. Combining these agents carries an additive risk of myopathy (muscle disease). Official patient information often contains a general recommendation that all vitamins and supplements be discussed with a healthcare professional.


Q: Is it safe to drink alcohol while taking Preschol?

Official regulatory information indicates that using Preschol with substantial quantities of alcohol may increase the risk of developing liver problems. This is due to the way both the medicine and alcohol affect liver function.


Q: How is Preschol different from a generic version?

Regulatory agencies classify a generic version of Preschol (Simvastatin) as identical to the brand name drug. This classification means they are the same in dosage form, strength, quality, performance, and basic instructions for use.


Q: What happens when you stop taking Preschol?

Regulatory information advises that the therapeutic benefits of Preschol rely on continuous, long-term use. If the medicine is stopped, the body’s cholesterol levels may return to the high levels they were at before treatment began.


Q: Does Preschol interact with common pain relievers like ibuprofen?

The official prescribing information for Preschol does not list common nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen as having a known or specific interaction.


Q: Is it common to have nausea when starting Preschol?

Official documents list Nausea as a reported adverse reaction. This is categorized as a general side effect of the medicine.


Q: Are there any special monitoring tests required while on Preschol?

Official guidance generally requires a Liver Function Test (LFT) before a patient starts taking Preschol. Monitoring may be undertaken throughout treatment, particularly given the regulatory concern about potential liver issues, such as elevated liver transaminases.


Q: Does Preschol affect blood sugar levels?

Safety communications from regulatory agencies have reported that small increases in blood sugar levels have been observed with statin use. This includes changes in HbA1 c (average blood sugar) and fasting glucose levels.


Q: Where can I find official summaries of Preschol's clinical trials?

Official summaries and detailed information about the clinical trials for Preschol can be accessed on government-run databases. Key sources include the National Institutes of Health (NIH) ClinicalTrials.gov website.


Q: Why does the official document mention genetic testing before using Preschol?

The official label notes that a significant percentage of muscle injury cases were associated with a genetic variant (SLCO1B1). This specific genetic factor affects how the medicine is transported into the liver, which may be associated with higher concentrations in the bloodstream and an increased risk of myopathy (muscle injury).


Q: What should I do if I think I'm having a rare side effect from Preschol?

Regulatory bodies recommend that individuals contact their healthcare professional promptly if they experience any unexplained symptoms or potential side effects. The official instructions also mention that adverse events can be reported directly to the relevant national drug safety or pharmacovigilance program.


Q: Does Preschol require a special diet?

Official instructions specify that Preschol is recommended to be used in combination with a standard cholesterol-lowering diet. This diet is expected to be maintained throughout the course of treatment.


Q: What does the official guidance say about Preschol and elderly patients?

Official guidance specifically addresses usage in the elderly population. The documents indicate that no general dosage adjustment is necessary for elderly patients.

How should Preschol be stored and disposed of?

How to Store and Dispose of Preschol (Simvastatin)

Preschol tablets must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container and protected from both light and moisture. Temperatures outside of the allowed excursion range of 15 C to 30 C must be avoided.

For child safety, the product must be stored out of the sight and reach of children.

Disposal Requirements

Official instructions require unused or expired tablets to be disposed of according to local state and city regulations or through an authorized drug take-back program. It is strictly prohibited to dispose of the medication by flushing it into wastewater or placing it in household trash, unless specifically instructed by a disposal authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Preschol found in:

A-Z Index: